WA-AMAZON-WEB-SERVICES
1.12.2021 15:02:06 CET | Business Wire | Press release
Today, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that Aurora (NASDAQ: AUR), a leader in self-driving vehicle technology, has selected AWS as its preferred cloud provider for machine learning training and cloud-based simulation workloads. Aurora uses AWS’s proven infrastructure and unparalleled portfolio of capabilities to safely accelerate the development of the Aurora Driver, its scalable self-driving vehicle technology. The Aurora Driver consists of sensors that perceive the world, software that plans a safe path through it, and a computer that powers and integrates Aurora’s hardware and software with any vehicle platform. For its machine learning training and cloud-based simulation workloads, Aurora is all-in on AWS, and it uses the cloud to process trillions of data points each day. Now, the company is scaling its training workloads in the cloud to complete up to 12 million physics-based driving simulations per day by the end of the year, building on the petabytes of data it collects during real-world road tests.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005041/en/
Autonomous driving is an immensely complex technological challenge that relies heavily on cloud computing to enable breakthroughs in perception, embedded computing, machine learning, motion planning, decision making, and advanced sensor technologies. With AWS’s capabilities in high-performance computing, machine learning, storage, and security, Aurora optimizes and scales its virtual testing efforts to expand the capabilities of the Aurora Driver safely and quickly.
“Aurora’s advanced machine learning and simulation at scale are foundational to developing our technology safely and quickly, and AWS delivers the high performance we need to maintain our progress,” said Chris Urmson, CEO of Aurora. “With its virtually unlimited scale, AWS supports millions of virtual tests to validate the capabilities of the Aurora Driver so that it can safely navigate the countless edge cases of real-world driving.”
Aurora’s AWS-powered Virtual Testing Suite is a unique accelerator for the development of the Aurora Driver. Aurora can use data from just one testing situation it observes in the real world to inspire hundreds of permutations in the Virtual Testing Suite. That virtual testing helps train the Aurora Driver to more quickly and safely navigate complex situations, such as road construction, jaywalkers, and unprotected left-hand turns. For example, before the Aurora Driver ever attempted an unprotected left-hand turn on a physical road, it completed nearly 2.3 million turns in simulation—estimated to be roughly equal to 20,000 hours of real-world driving practice. Aurora has been running simulations at scale on AWS since 2019, and plans to triple the volume of simulations it runs on AWS to more than 12 million per day by the end of 2021.
The offline components of the Aurora Driver software stack all run on AWS, including the Virtual Testing Suite, high-definition road maps (the Aurora “Atlas”), machine learning models, and software development tools. For example, Aurora uses Amazon SageMaker (an AWS service that helps developers and data scientists build, train, and deploy machine learning models quickly) to create, run, and continuously refine the machine learning models that enable its driving simulations. With that service, Aurora accesses Amazon Elastic Compute Cloud (Amazon EC2) instance types like P4d, which deliver the highest performance for machine learning training in the cloud.
Before developing simulations, Aurora uses AWS to securely store and process the petabytes of data it logs during real-world testing, and then train its machine learning models on that data. The pre-processing workloads run on Amazon Elastic Kubernetes Service (Amazon EKS) and Amazon EMR, AWS’s service for processing vast amounts of data in the cloud using open-source tools. Aurora’s machine learning training workloads then rely on AWS-optimized deep learning frameworks, such as TensorFlow and PyTorch. Finally, Aurora orchestrates and auto-scales its simulation workflows over hundreds of thousands of concurrent vCPUs and thousands of concurrent GPUs with Amazon EKS and Amazon EC2, which provides accelerated computing instance types like G4dn.
“AWS’s highly scalable compute, machine learning, and analytics services are helping Aurora move self-driving vehicle technology forward, toward broad real-world use,” said Swami Sivasubramanian, Vice President of Machine Learning at Amazon Web Services, Inc. “Our reliable infrastructure and comprehensive set of cloud services, including industry-leading machine learning services like Amazon SageMaker, provide the ideal foundation for Aurora to gain insights from the trillions of data points it generates every day to continuously enhance its technology. We are proud to support the acceleration of autonomous vehicle innovation, and look forward to the improved safety and efficiency the transformation of trucking, delivery, and mobility will allow.”
About Amazon Web Services
For over 15 years, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud offering. AWS has been continually expanding its services to support virtually any cloud workload, and it now has more than 200 fully featured services for compute, storage, databases, networking, analytics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management from 81 Availability Zones within 25 geographic regions, with announced plans for 27 more Availability Zones and nine more AWS Regions in Australia, Canada, India, Indonesia, Israel, New Zealand, Spain, Switzerland, and the United Arab Emirates. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit aws.amazon.com .
About Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Amazon strives to be Earth’s Most Customer-Centric Company, Earth’s Best Employer, and Earth’s Safest Place to Work. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Career Choice, Fire tablets, Fire TV, Amazon Echo, Alexa, Just Walk Out technology, Amazon Studios, and The Climate Pledge are some of the things pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.
About Aurora
Founded in 2017 by experts in the self-driving industry, Aurora is on a mission to deliver the benefits of self-driving technology safely, quickly, and broadly. To move both people and goods, the company is building the Aurora Driver, a platform that brings together software, hardware and data services to autonomously operate passenger vehicles, light commercial vehicles, and heavy-duty trucks. Aurora is backed by Sequoia Capital, Baillie Gifford, funds and accounts advised by T. Rowe Price Associates, among others, and is partnered with industry leaders including Toyota, Uber, Volvo, and PACCAR. Aurora tests its vehicles in the Bay Area, Pittsburgh, and Dallas. The company has offices in those areas as well as in Bozeman, MT; Seattle, WA; Louisville, CO; and Wixom, MI. To learn more, visit www.aurora.tech .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005041/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom